Clinical Laserthermia Systems (DB:LS60) - Hisse Senedi Fiyatı, Haberler ve Analizler

LS60 Stoklara Genel Bakış

Clinical Laserthermia Systems AB (publ), İsveç'te TRANBERG markası altında hastalıklı dokular için tedavi araçları geliştirmektedir. Daha fazla detay

LS60 temel anali̇z
Kar Tanesi Skoru
Değerleme	1/6
Gelecekteki Büyüme	2/6
Geçmiş Performans	0/6
Finansal Sağlık	4/6
Temettüler	0/6

Ödüller

Gelirin yılda 51.87% oranında artması öngörülüyor

Risk Analizi

Anlamlı bir piyasa değeri yok ( €61M )

Hissedarlar geçen yıl önemli ölçüde sulandırıldı

1 yıldan az nakit akışı var

Son 3 ayda hisse senedi fiyatı oldukça dalgalıydı

+ 2 daha fazla risk

Clinical Laserthermia Systems AB (publ) Rakipler

Audientes

DB:AUG

€6.9m

Geratherm Medical

XTRA:GME

€28.5m

aap Implantate

XTRA:AAQ1

€22.2m

PULSION Medical Systems

MUN:PUS

€133.6m

Fiyat Geçmişi ve Performans

için tüm zamanların en yüksek seviyelerinin, değişikliklerin ve fiyat düşüşlerinin özeti Clinical Laserthermia Systems
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı	SEK 0.32
52 Haftanın En Yüksek Seviyesi	SEK 7.80
52 Haftanın En Düşük Seviyesi	SEK 0.04
Beta	0.21
11 Aylık Değişim	-17.17%
3 Aylık Değişim	-24.20%
1 Yıllık Değişim	-75.91%
33 Yıllık Değişim	-99.61%
5 Yıllık Değişim	-99.83%
Halka arzdan bu yana değişim	-99.80%

Son Haberler & Güncellemeler

Recent updates

Hissedar Getirileri

	LS60	DE Medical Equipment	DE Pazar
7D	16.9%	3.8%	1.3%
1Y	-75.9%	-6.6%	7.9%

Getiri vs. Endüstri: LS60 geçen yıl % -6.6 oranında getiri sağlayan German Medical Equipment sektörünün gerisinde kaldı.

Getiri vs Piyasa: LS60 geçen yıl % 7.9 oranında getiri sağlayan German Piyasasının altında performans gösterdi.

Fiyat Oynaklığı

Is LS60's price volatile compared to industry and market?
LS60 volatility
LS60 Average Weekly Movement	21.6%
Medical Equipment Industry Average Movement	6.2%
Market Average Movement	4.8%
10% most volatile stocks in DE Market	10.8%
10% least volatile stocks in DE Market	2.4%

İstikrarlı Hisse Senedi Fiyatı: LS60 hisse senedi fiyatı son 3 aydır dalgalı bir seyir izliyor.

Zaman İçindeki Volatilite: LS60 'nin haftalık oynaklığı son bir yılda 195% dan 22% a düştü, ancak hâlâ German hisselerinin %75'inden yüksek.

Şirket Hakkında

Kuruldu	Çalışanlar	CEO	Web sitesi
2006	17	Dan Mogren	www.clinicallaser.se

Clinical Laserthermia Systems AB (publ), İsveç'te TRANBERG markası altında hastalıklı dokular için tedavi araçları geliştirmektedir. Şirket, hedef dokuyu ısıtmak için lazer enerjisi sağlamak üzere tasarlanmış bir termal terapi sistemi olan TRANBERG'i sunmaktadır. Ayrıca, tedaviyi kontrol etmek için çoklu seçenekler sunan 1064 nanometre dalga boyuna sahip bir kontrol bileşeni olan mobil lazer ünitesi de sağlamaktadır.

Clinical Laserthermia Systems AB (publ) Temel Bilgiler Özeti

Clinical Laserthermia Systems'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
LS60 temel i̇stati̇sti̇kler
Piyasa değeri	€5.27m
Kazançlar(TTM)	-€5.57m
Gelir(TTM)	€1.62m

3.3x

P/S Oranı

-0.9x

F/K Oranı

LS60 aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
LS60 gelir tablosu (TTM)
Gelir	SEK 18.63m
Gelir Maliyeti	SEK 11.53m
Brüt Kâr	SEK 7.10m
Diğer Giderler	SEK 71.30m
Kazançlar	-SEK 64.20m

Son Raporlanan Kazançlar

Sep 30, 2024

Sonraki Kazanç Tarihi

Feb 21, 2025

Hisse başına kazanç (EPS)	-4.61
Brüt Marj	38.09%
Net Kâr Marjı	-344.68%
Borç/Özkaynak Oranı	2.0%

LS60 uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

LS60 Stoklara Genel Bakış

Ödüller

Risk Analizi

Clinical Laserthermia Systems AB (publ) Rakipler

DB:AUG

€6.9m

XTRA:GME

€28.5m

XTRA:AAQ1

€22.2m

MUN:PUS

€133.6m

Fiyat Geçmişi ve Performans

Son Haberler & Güncellemeler

Third quarter 2024 earnings released

Clinical Laserthermia Systems AB (publ) Approves Board Appoints

Clinical Laserthermia Systems AB (Publ) Announces Board Resignations

Insufficient new directors

Second quarter 2024 earnings released

New major risk - Shareholder dilution

Recent updates

Third quarter 2024 earnings released

Clinical Laserthermia Systems AB (publ) Approves Board Appoints

Clinical Laserthermia Systems AB (Publ) Announces Board Resignations

Insufficient new directors

Second quarter 2024 earnings released

New major risk - Shareholder dilution

Clinical Laserthermia Systems AB (publ) Announces Completion of Clinical Study At Skane University Hospital

First quarter 2024 earnings released

Clinical Laserthermia Systems AB (Pub) Announces Two Patients with Localized Prostate Cancer Have Been Safely Treated with the Tranberg Thermal Therapy System At the San Luigi Gonzaga University Hospital in Turin, Italy

Clinical Laserthermia Systems AB (publ) Announces CFO Changes

Clinical Laserthermia Systems AB (publ) Announces Publication of Preclinical Assessment of A Non-Cooled MR Thermometry-Based Neurosurgical Laser Therapy System

New major risk - Revenue and earnings growth

Full year 2023 earnings released: kr0.06 loss per share (vs kr0.85 loss in FY 2022)

Clinical Laserthermia Systems AB (publ) to Report Q2, 2024 Results on Aug 23, 2024

Clinical Laserthermia Systems AB (Publ) Files A New Patent Application for Expanded and Extended Protection of the Company's Technology for Laser-Based Tissue Ablation Until 2044

Clinical Laserthermia Systems AB (publ) Receives Market Approval for Its TRANBERG Portfolio by HSA in Singapore and Initiates the Process of Commercialization in the Region

Clinical Laserthermia Systems AB (publ) Announces Members of the Nomination Committee Appointments

Clinical Laserthermia Systems AB (publ) Announces Executive Changes

Clinical Laserthermia Systems AB (publ) Announces First Patient was Safely Treated with CLS TRANBERG® Thermal Therapy system for laser ablation of Prostate Cancer

High number of new directors

Third quarter 2023 earnings released

Clinical Laserthermia Systems AB (publ) Announces Enrollment Completion of Initial Phase and Extension of Clinical Trial at Radboud University Medical Center

Clinical Laserthermia Systems AB (publ) Announces Resignation of Rolf Ho Bornschein as CFO

Second quarter 2023 earnings released

Clinical Laserthermia Systems AB (publ), Annual General Meeting, Jun 29, 2023

First quarter 2023 earnings released

Clinical Laserthermia Systems AB Appoints Jimmy Johansson as Executive VP Operations

Full year 2022 earnings released: kr0.57 loss per share (vs kr1.11 loss in FY 2021)

Clinical Laserthermia Systems AB (Publ) Announces First Glioblastoma Patient Treated with the Mr-Guided Laser Interstitial Thermal Therapy (MRg LITT) in the Study At Skåne University Hospital

Third quarter 2022 earnings released

High number of new and inexperienced directors

BioStock Studio Announces FDA clearance

Clinical Laserthermia Systems Receives 510(K) Clearance for Its MR Guided Laser Ablation System in Neurosurgery and Initiates Commercialization

Second quarter 2022 earnings released

Clinical Laserthermia Systems AB (publ) Appoints Rolf Ho Bornschein as the New CFO, Effective October 1, 2022 Replacing Lars-Erik Eriksson

Clinical Laserthermia Systems AB (publ) to Report Fiscal Year 2022 Final Results on Feb 23, 2023

Clinical Laserthermia Systems AB (Publ) Appoints Dan J. Mogren as Permanent CEO

Clinical Laserthermia Systems AB's Subsidiary CLS Americas Announces First Patient Treated in Clinical Study Targeted MRI/ US Fusion Transperineal Laser Ablation of Low-To-Intermediate Risk Prostate Cancer

Clinical Laserthermia Systems AB (publ) Releases Ce-Marked New Version of Thermoguide™ Workstation for Use Also with Mri Scanners from GE Healthcare

Clinical Laserthermia Systems AB (Publ) Announces CEO Changes

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Clinical Laserthermia Systems AB (publ) Announces CEO Changes

Clinical Laserthermia Systems AB (publ) Files 510 (K) Application with the U.S. Food and Drug Administration for the Second Generation of TRANBERG®

Clinical Laserthermia Systems AB (Publ) Again Releases Tranberg® Sterile Disposable Products on the European Market and Enters into an Agreement with Two Additional Suppliers of Sterilization Services

Third quarter 2021 earnings released

Clinical Laserthermia Systems AB (Publ) to Present TRANBERG® Laser Thermal Therapy System and Latest Enhancements at the 73rd Congress of the German Society for Urology Conference

Second quarter 2021 earnings released

Clinical Laserthermia Systems AB (publ) and Toronto General Hospital Resume Clinical Trial for Prostate Cancer as Company Receives Approval for Updated Sterilization Process by Health Canada

Clinical Laserthermia Systems AB (publ) and University Hospital Magdeburg Obtains the Go for the Investigator Initiated Trial on Focal Laser Ablation Treatment of Localized Prostate Cancer, with the TRANBERG

First quarter 2021 earnings released

Full year 2020 earnings released: kr1.24 loss per share (vs kr1.25 loss in FY 2019)

New 90-day low: €0.39

New 90-day low: €0.42

New 90-day low: €0.45

New 90-day low: €0.59

Clinical Laserthermia Systems AB (Publ) and Toronto General Hospital Continue Clinical Trial Collaboration Regarding MRI-Guided Laser Ablation Treatment of Prostate Cancer

CLS Receives New CPT® Reimbursement Code Approval by American Medical Association for Ultrasound-Guided Focal Laser Ablation of Prostate Cancer

New 90-day low: €0.65

Clinical Laserthermia Systems AB (Publ) and University Hospital Magdeburg Launch Clinical Trial Regarding Focal Laser Ablation Treatment of Localized Prostate Cancer